Understanding how drug combinations affect resistance to new antimalarial treatments
Official title: Interactions between drug combinations and resistance acquisition risk for antimalarial ATP4 inhibitors
Funded at University of Kentucky · NIH-11110440 · Data updated 2026-11-12
This study is looking at new fast-acting malaria drugs to see how well they work together with other medications to stop malaria from becoming resistant to treatment, helping to improve options for people in areas where drug resistance is a big problem.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Kentucky NIH-funded |
| Lab location | 1 site (Lexington, United States) |
| Project start | June 7, 2024 |
| Project end | May 31, 2029 |
| Funding year | 2025 |
| Award (this year) | $755,713 |
| NIH project number | 5R01AI184710-02 |
| Project ID | NIH-11110440 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals living in malaria-endemic regions, particularly those infected with P. falciparum or P. vivax.
✕Less likely to help
Patients who are not infected with malaria or those living in non-endemic regions may not benefit from this research.
What this research studies
This research investigates the effectiveness of new fast-acting antimalarial drugs, specifically ATP4 inhibitors, and how different drug combinations can prevent the development of drug-resistant malaria strains. By studying both laboratory and live models, the research aims to identify which combinations of existing antimalarial medications work best with ATP4 inhibitors to reduce the risk of resistance. The goal is to enhance treatment options for malaria, particularly in regions where drug resistance is a significant concern.
Why it matters
Potential benefit: If successful, this research could lead to the development of more effective antimalarial treatments that are less likely to result in drug resistance.
How similar studies have gone: Previous research has shown promise in developing combination therapies for malaria, indicating that this approach could be effective.
Where this research is happening
-
University of Kentucky
Lexington, United States Active
Researchers
- Principal investigator: Guy, Rodney Kiplin — University of Kentucky
- Study coordinator: Guy, Rodney Kiplin
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.